Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Adma Biologics (ADMA) Amortization - Intangibles: 2017-2024

Historic Amortization - Intangibles for Adma Biologics (ADMA) over the last 7 years, with Dec 2024 value amounting to $400,000.

  • Adma Biologics' Amortization - Intangibles rose 35.71% to $38,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $132,000, marking a year-over-year decrease of 76.00%. This contributed to the annual value of $400,000 for FY2024, which is 44.75% down from last year.
  • Per Adma Biologics' latest filing, its Amortization - Intangibles stood at $400,000 for FY2024, which was down 44.75% from $724,000 recorded in FY2023.
  • Adma Biologics' 5-year Amortization - Intangibles high stood at $724,000 for FY2023, and its period low was $400,000 during FY2024.
  • For the 3-year period, Adma Biologics' Amortization - Intangibles averaged around $613,000, with its median value being $715,000 (2022).
  • As far as peak fluctuations go, Adma Biologics' Amortization - Intangibles rose by 1.26% in 2023, and later plummeted by 44.75% in 2024.
  • Adma Biologics' Amortization - Intangibles (Yearly) stood at $715,353 in 2020, then declined by 0.05% to $715,000 in 2021, then remained steady at $715,000 in 2022, then climbed by 1.26% to $724,000 in 2023, then tumbled by 44.75% to $400,000 in 2024.